"It also could lead to a broader impact on people's access to these drugs, sinceMedicare often influences what private insurers choose to cover. The Wall Street Journal reported that the deal could also allow Medicaid coverage of the drugs. Endpoints News first reported the details of the emergingdeal. Context: Medicare already covers GLP-1s for diabetes, heart disease and sleep apnea, and about half of seniors with obesity are already eligible for the drugs due to other conditions."
"In April,the Trump administration scrapped a Biden-era proposal to let Medicare and Medicaid cover GLP-1s to treat obesity. The plan would have cost some $40 billion over 10 years. This would be the latest in a line of deals between the White House and drugmakers to lower drug prices paid by Americans. This is a developing story. Check back for updates."
A deal could allow Medicaid coverage of GLP-1 drugs and influence private insurers, potentially broadening patient access. Medicare already covers GLP-1s for diabetes, heart disease, and sleep apnea, and about half of seniors with obesity are eligible for the drugs because of other covered conditions. An April decision by the Trump administration eliminated a previous proposal to let Medicare and Medicaid cover GLP-1s for obesity; that proposal was estimated to cost roughly $40 billion over ten years. The arrangement would fit into an ongoing pattern of White House agreements with drugmakers aimed at lowering drug prices for Americans.
Read at Axios
Unable to calculate read time
Collection
[
|
...
]